Oxis International (OTC: OXIS) operates through a wholly owned subsidiary, Oxis Biotech, Inc., to develop immunotherapies for the treatment of cancer and other unmet medical needs. The company’s OXS-2175 candidate targets the treatment of triple-negative breast cancer. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug’s cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. For more information, visit the company’s website at www.oxis.com